TITLE

Elements: In this month's issue

AUTHOR(S)
Bannon, Michael
PUB. DATE
May 2010
SOURCE
QJM: An International Journal of Medicine;May2010, Vol. 103 Issue 5, p283
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses various reports published within the issue, including one on Hepatitis C viral infection (HCV) and hepatic steatosis, one on intravenous proton pump inhibitors, and another one on the impact of the H1N1 epidemic in South Africa.
ACCESSION #
50346333

 

Related Articles

  • Proton Pump Inhibitors Increase the Incidence of Bone Fractures in Hepatitis C Patients. Mello, Michael; Weideman, Rick; Little, Bertis; Weideman, Mark; Cryer, Byron; Brown, Geri // Digestive Diseases & Sciences;Sep2012, Vol. 57 Issue 9, p2416 

    Background: While proton pump inhibitors (PPI) may increase the risk of bone fractures, the incidence of new bone fractures in a chronic hepatitis C virus (HCV) infected cohort, with or without PPI exposure, has not been explored. Methods: A retrospective cohort study of the incidence of bone...

  • Lack of a clinically significant drug–drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. de Kanter, Clara T. M. M.; Colbers, Angela P. H.; Blonk, Maren I.; Verweij-van Wissen, Corrien P. W. G. M.; Schouwenberg, Bas J. J. W.; Drenth, Joost P. H.; Burger, David M. // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1415 

    Objectives Proton pump inhibitors (PPIs) can limit the solubility of concomitant drugs, which can lead to decreased absorption and exposure. Reduced efficacy can be a consequence and in the case of an antimicrobial agent this may contribute to development of resistance. Patients chronically...

  • Correction. Lin, Kenneth W.; Siwek, Jay // American Family Physician;10/15/2012, Vol. 86 Issue 8, p727 

    A correction to the article "Reducing Adverse Effects of Proton Pump Inhibitors," by Ament et al. in the July 1, 2012 issue is presented.

  • Studies in Healthy Volunteers do not Show any Electrocardiographic Effects with Esomeprazole. Hasselgren, B.; Claar-Nilsson, C.; Hasselgren, G.; Niazi, M.; Svernhage, E. // Clinical Drug Investigation;2000, Vol. 20 Issue 6, p425 

    Objectives: Esomeprazole is the first proton pump inhibitor developed as an optical isomer. The aim of this study was to assess the potential effects of this agent on the electrocardiogram (ECG) in healthy volunteers. Study Participants and Methods: A pooled analysis was performed of 82 healthy...

  • Pantoprazole: An Update of its Pharmacological Properties and Therapeutic Use in the Management of Acid-Related Disorders. Cheer, S.M.; Prakash, A.; Faulds, D.; Lamb, H.M. // Drugs;2003, Vol. 63 Issue 1, p101 

    Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion. In combination with two antimicrobial agents (most commonly metronidazole, clarithromycin or amoxicillin) for 6-14 days, pantoprazole 40mg twice daily produced Helicobacter pylori...

  • Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study. Claessens, A.A.M.C.; Heerdink, E.R.; van Eijk, J.T.H.M.; Lamers, C.B.H.W.; Leufkens, H.G.M.; Claessens, Angela A M C; Heerdink, Eibert R; van Eijk, Jacques T H M; Lamers, Cornelis B H W; Leufkens, Hubert G M // Drug Safety;Feb2002, Vol. 25 Issue 4, p287 

    Objective: During proton pump inhibitor (PPI) use, in clinical trials, headache is one of the most frequently reported adverse events (frequency 1.3 to 8.8%), while results of one observational study indicate that headache is the fifth most frequently reported adverse event...

  • omeprazole.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1628 

    A definition of the term "omeprazole" which refers to an inhibitor of the gastric acid formation is presented.

  • Correction.  // Neurology Alert;Jul2009 Pharmacology Watch, p2 

    A correction to an article on the approval of a new proton pump inhibitor, published in the May 2009 issue, is presented.

  • Correction.  // Primary Care Reports;Jul2009 Pharmacology Watch, p2 

    This section presents a correction to an article about lansoprazole brand Prevacid⪚, published in the May 2009 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics